

Fremanezumab for preventive treatment of migraine

Functional status on headache-free days

Juliana VanderPluym, MD, David W. Dodick, MD, Richard B. Lipton, MD, et al.

Cite as: *Neurology*® 2018;91:e1152-e1165. doi:10.1212/01.wnl.0000544321.19316.40

Correspondence

Dr. VanderPluym
VanderPluym.Juliana@mayo.edu

Study objective

To determine if fremanezumab improves functional performance on headache-free days (HFDs) for patients with migraine.

Summary results

Patients with migraine receiving fremanezumab had more HFDs with normal functional performance.

Classification of evidence

Class II.

What is known and what this paper adds

Migraine can impair functional performance during interictal periods. This study shows that patients receiving fremanezumab had more HFDs with normal functional performance.

Participants and setting

This study examined 297 patients with high-frequency episodic migraine (HFEM; i.e., 8–14 monthly headache days) and 263 patients with chronic migraine (CM; i.e., >15 monthly headache days) at 62 US sites between January 2014 and January 2015.

Design, size, and duration

This double-blind study assigned participants to treatment groups via central randomization. The participants with HFEM received placebo (n = 104) or fremanezumab at 225 mg/month (n = 96) or 675 mg/month (n = 97), and the participants with CM received placebo (n = 89) or fremanezumab at 675 mg (month 1) followed by 225 mg/month (n = 88) or 900 mg/month (n = 86). Participants used a daily electronic diary for 3 months. The functional outcomes included work/school/household chore performance, speed of work completion, concentration, and feeling of fatigue.


Primary outcome measures

The primary outcomes were the differences between the placebo- and fremanezumab-treated participants in functional performance on HFDs.

Main results and the role of chance

In the HFEM group, patients receiving fremanezumab consistently had more HFDs with normal functional performance in all measures ($p < 0.005$). In the CM group, patients on

Figure Effect of fremanezumab on the number of HFDs



** $p < 0.01$, *** $p < 0.001$.

fremanezumab had increased HFDs with normal functional performance on some measures, such as freedom from concentration difficulties ($p \leq 0.0284$).

Harms

No major drug-related adverse events were noted.

Bias, confounding, and other reasons for caution

Drug-related side effects might have unblinded some patients. This study did not use standardized questionnaires.

Generalizability to other populations

The lack of non-US sites may limit the generalizability of this study's results.

Study funding/potential competing interests

This study was funded by Teva. Some authors report receiving lecture honoraria, consulting fees, advisory board appointments or owning equity or serving on the boards of directors for healthcare companies; owning a patent; receiving editorial fees, travel/lecture fees, and royalty payments from various science publishers; and receiving grants from various foundations and the NIH. Go to Neurology.org/N for full disclosures.

Trial registration number

NCT02025556 and NCT02021773 on ClinicalTrials.gov.

A draft of the short-form article was written by M. Dalefield, a writer with Editage, a division of Cactus Communications. The authors of the full-length article and the journal editors edited and approved the final version.

Neurology[®]

Fremanezumab for preventive treatment of migraine: Functional status on headache-free days

Juliana VanderPluym, David W. Dodick, Richard B. Lipton, et al.
Neurology 2018;91:e1152-e1165 Published Online before print August 17, 2018
DOI 10.1212/01.wnl.0000544321.19316.40

This information is current as of August 17, 2018

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/91/12/e1152.full
References	This article cites 36 articles, 7 of which you can access for free at: http://n.neurology.org/content/91/12/e1152.full#ref-list-1
Citations	This article has been cited by 7 HighWire-hosted articles: http://n.neurology.org/content/91/12/e1152.full##otherarticles
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): All Headache http://n.neurology.org/cgi/collection/all_headache Migraine http://n.neurology.org/cgi/collection/migraine
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

